Insta
China Approves Clinical Trials For 16 COVID-19 Vaccine Candidates; Six Already In The Third Stage
Swarajya Staff
Feb 22, 2021, 05:43 PM | Updated 05:43 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
In a big push towards the development of vaccines to tackle the continuing menace of COVID-19, China has approved clinical trials for 16 indigenous vaccine candidates, six of which are already in the third stage, reports Economic Times.
The latest set of vaccine candidates are said to based on recombinant protein, adenovirus vector, nucleic acid and attenuates influenza-viruses technologies as per the data from National Medical Products Administration.
Meanwhile, it should be noted that the authorities in China have already accorded conditional approval to two inactivated COVID-19 vaccines developed by state-owned firms Sinopharm and Sinovac Biotech.
As per the Chinese state-run media Xinhua, as of 9 February, China had completed vaccinating 40.52 million people in the key groups. The nation has so far reported 4,833 deaths and 1,00,727 confirmed cases.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.